共 50 条
- [4] Real-World Treatment Outcomes in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Were Treated With First-Line Single-Agent Ibrutinib vs Chemoimmunotherapy CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S330 - S330
- [5] Real-World Adherence to First-Line Ibrutinib and Acalabrutinib Single-Agent Among Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S280 - S281
- [9] Retrospective Analysis of Real-World Outcomes of Chronic/ Small Lymphocytic Leukemia (CLL/SLL) Patients Treated With First-Line Ibrutinib Versus Chemoimmunotherapy (CIT) CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S275 - S276